补充C3a受体对抗剂缓解tau病理并改善P301S小鼠的认知缺陷
Yi Yao1, Yanmin Chang2, Shaomin Li3
1Department of Neurology, Wuhan Fourth Hospital, Wuhan, 430033 Hubei, China.
Brain research bulletin
|June 17, 2023
概括
阻断补充C3a受体 (C3aR) 会减少陶的过酸化,并改善老鼠阿尔茨海默病 (AD) 模型中的记忆. 这一发现凸显了C3aR作为包括AD在内的陶病症的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 包括阿尔茨海默氏症 (AD) 在内的病症涉及过酸化的蛋白积累.
- 补体系统,特别是补体C3a受体 (C3aR),与病症和AD病变发生有关.
- 将C3aR激活与Tau过酸化联系在一起的机制尚不清楚.
研究的目的:
- 调查C3aR在调解Tau过酸化和认知缺陷中的作用,在病和AD的小鼠模型中.
- 探索C3aR作为潜在的治疗点,用于病障碍.
主要方法:
- 在P301S小鼠中检查了C3aR表达 (病和AD的模型).
- 在P301S小鼠中使用C3aR抗剂 (SB 290157).
- 评估了突触完整性,Tau高酸化和空间记忆 (莫里斯水迷宫).
- 研究了p35/CDK5信号通路的调节.
主要成果:
- 在P301S小鼠的大脑中,C3aR表达被上调.
- 药理上对C3aR的阻断改善了突触完整性,并减少了Tau过酸化.
- 用C3aR抗剂改善了P301S小鼠的空间记忆.
- 通过调节p35/CDK5信号传递,C3aR对抗作用抑制了Tau过酸化.
结论:
- 在P301S小鼠中,C3aR在高酸化Tau的积累和行为缺陷中起着重要作用.
- 准C3aR为包括阿尔茨海默病在内的多病症提供了一个有前途的治疗策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
165
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
165